• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia

Exclusive

An hour in the Oval Office with President Trump Fortune Editor-in-Chief: Alyson Shontell sat down with President Trump in the Oval Office for an hour. Tariffs, Intel, AI, Boeing, Iran—and the question every CEO eventually has to answer: who's next?

An hour in the Oval Office with President Trump Fortune Editor-in-Chief: Alyson Shontell sat down with President Trump in the Oval Office for an hour. Tariffs, Intel, AI, Boeing, Iran—and the question every CEO eventually has to answer: who's next?

An hour in the Oval Office with President Trump Fortune Editor-in-Chief: Alyson Shontell sat down with President Trump in the Oval Office for an hour. Tariffs, Intel, AI, Boeing, Iran—and the question every CEO eventually has to answer: who's next?

An hour in the Oval Office with President Trump Fortune Editor-in-Chief: Alyson Shontell sat down with President Trump in the Oval Office for an hour. Tariffs, Intel, AI, Boeing, Iran—and the question every CEO eventually has to answer: who's next?

An hour in the Oval Office with President Trump Fortune Editor-in-Chief: Alyson Shontell sat down with President Trump in the Oval Office for an hour. Tariffs, Intel, AI, Boeing, Iran—and the question every CEO eventually has to answer: who's next?

An hour in the Oval Office with President Trump Fortune Editor-in-Chief: Alyson Shontell sat down with President Trump in the Oval Office for an hour. Tariffs, Intel, AI, Boeing, Iran—and the question every CEO eventually has to answer: who's next?

An hour in the Oval Office with President Trump Fortune Editor-in-Chief: Alyson Shontell sat down with President Trump in the Oval Office for an hour. Tariffs, Intel, AI, Boeing, Iran—and the question every CEO eventually has to answer: who's next?

An hour in the Oval Office with President Trump Fortune Editor-in-Chief: Alyson Shontell sat down with President Trump in the Oval Office for an hour. Tariffs, Intel, AI, Boeing, Iran—and the question every CEO eventually has to answer: who's next?

An hour in the Oval Office with President Trump Fortune Editor-in-Chief: Alyson Shontell sat down with President Trump in the Oval Office for an hour. Tariffs, Intel, AI, Boeing, Iran—and the question every CEO eventually has to answer: who's next?

An hour in the Oval Office with President Trump Fortune Editor-in-Chief: Alyson Shontell sat down with President Trump in the Oval Office for an hour. Tariffs, Intel, AI, Boeing, Iran—and the question every CEO eventually has to answer: who's next?

ConferencesBrainstorm Health

Can the pandemic-induced collaboration among health care companies have a real impact on inequality?

Sheryl Estrada
By
Sheryl Estrada
Sheryl Estrada
Senior Writer and author of CFO Daily
Down Arrow Button Icon
Sheryl Estrada
By
Sheryl Estrada
Sheryl Estrada
Senior Writer and author of CFO Daily
Down Arrow Button Icon
April 29, 2021, 11:45 AM ET

Science-based efforts to combat the spread of COVID-19 prompted partnerships within the health care, biotech, and pharmaceutical industries, rapid implementation of advanced technology, and the creation of groundbreaking vaccines.

“There’s so much collaboration, cooperation going on,” Daniel O’Day, chairman and CEO of Gilead Sciences, said at Fortune’s Brainstorm Health virtual conference on Wednesday. “The only competition in COVID is the virus itself. Companies have come together and collaborated in ways that we’ve never seen before. I’m optimistic that we’re going to continue to do that.”

At Brainstorm Health, CEOs leading health care and pharmaceutical companies discussed how they plan to harness the ingenuity of the past year to address existing health inequities amplified by the pandemic.

‘You realize that speed is of the essence’

A report released on April 28 by the Centers for Disease Control and Prevention found that among fully vaccinated adults age 65 and older the Pfizer/BioNTech and Moderna COVID-19 vaccines were 94% effective against COVID-19 hospitalization.

These vaccines harness a new technology that has been wildly successful.

“When I asked them, ‘What are we going to do for a vaccine?’ they said, ‘We’re going to work on an mRNA,’” said Pfizer CEO Albert Bourla. “I said, ‘You realize if we are successful, that will be the first-ever vaccine or the first-ever medicine approved with mRNA technology.’”

The scientists had been working with mRNA for about two years and explained to him that the technology enables one to accomplish what typically takes months in just weeks. Bourla agreed with the scientists’ decision, but, under time constraints, knew that meant creating partnerships.

“You realize that speed is of the essence. If we do that, we have to go with a partner,’’ Bourla said. Pfizer obtained the help of a “good partner” in BioNTech, which they have known for two years, he said.

This year, Pfizer will exceed 2.5 billion doses produced globally, Bourla said.

But the Pfizer/BioNTech vaccine has to be stored at –70°C, requiring specialized freezers that are expensive. Many rural hospitals in the U.S. can’t afford these storage units. Bourla said the company will reveal plans later this year to make the vaccine “way more distribution friendly.”

‘We couldn’t afford to miss a beat’

“Today, one out of two [COVID] patients in the hospital are receiving remdesivir,” said Gilead’s O’Day.

Gilead Sciences has been a longtime producer in the world of antivirals and worked on remdesivir for more than a decade before positioning it to fight COVID. But even as Gilead scientists continued to work on remdesivir, they simultaneously focused on developing cancer medicines and combating HIV, said O’Day.

“As the world’s leading company that supports patients who have HIV, three out of four patients around the world are on Gilead medicine,” he said. “We couldn’t afford to miss a beat there.”

O’Day continued, “HIV, sadly, disproportionately affects marginalized communities. We do a lot with partners to make sure that those populations can have better access to health care, better access to prevention.”

Gilead plans to “double down” on its commitment, said O’Day. “We think about the disparities in health care that exist today in our country and the racial inequities that are going on, and it’s absolutely essential we double down in our programs.”

‘Upstream is our lane’

“We’ve learned how quickly advances in science can be incorporated into clinical practice,” said Marc Harrison, president and CEO of Intermountain Healthcare, a nonprofit health system based in Salt Lake City.

Although, “historically, health systems have been islands,” the pandemic has created a focus on collaboration, said Harrison. To that end, he keeps Greg Adams, chairman and CEO of Kaiser Permanente, “on speed dial.” The CEOs share best practices in addressing health care disparities, which includes addressing underlying systemic issues of race, education, and income, said Adams, who leads the Oakland-based system of health care providers and nonprofit health plans.

“Upstream is our lane,” Adams said. “We’re focused on prevention. We’re focused on keeping our communities healthy. We understand that lack of education, lack of employment, housing—all of it contributes to health; and it contributes to the excess medical costs that we have in this country.”

Adams continued, “We are looking at how we will provide virtual urgent care on demand across the country, with the goal of having that in place within Kaiser Permanente regions by September, and then moving across the country.”

Adams and Harrison agree that democratizing health data can bring equality to medicine.  

“We’re collecting data in every one of our clinical programs to understand areas where we are falling short for our neighbors,” said Harrison. Intermountain has partnered with “a number of other systems” to address the health care data issue with an upcoming venture, he said. “It will be an opportunity to have standardized approaches to how data is organized, so that patients can actually benefit from a free flow of information.”

‘Everything starts in the community’

Over the past year, CVS Health has been on the “front lines helping Americans prevail against the pandemic,” said Karen S. Lynch, president and CEO of the retail giant.

“We’re the largest health care provider that’s given over 15 million tests,” said Lynch. The company has also administered more than 10 million COVID-19 vaccine doses, she noted.

“What we learned with a pandemic is everything starts in the community,” Lynch explained. “We saw that with testing. We saw that with vaccines. I think we’ll continue to see more and more people focused on access to health care, locally. And I’ve always said health care is local, and that’s where it all starts.”

Going forward, the company will also focus on the social determinants of health, including housing, she said. In 2020, CVS Health invested more than $114 million in affordable housing to support the construction and rehabilitation of more than 2,800 affordable housing units in 30 cities across 12 states.

“No one worries about their health if they don’t have housing, they don’t have access to healthy foods, and they don’t have a job,” Lynch said.

More health care and Big Pharma coverage from Fortune:

  • Moderna is working toward a single shot for both COVID and flu protection
  • Pfizer’s COVID-19 treatment pill could be available by year’s end
  • West Virginia sets new bar for COVID vaccine incentives with $100 reward
  • Americans can travel to Europe this summer. But will they want to?
  • The 2021 Fortune/IBM Watson Health 100 Top Hospitals
About the Author
Sheryl Estrada
By Sheryl EstradaSenior Writer and author of CFO Daily
LinkedIn iconTwitter icon

Sheryl Estrada is a senior writer at Fortune, where she covers the corporate finance industry, Wall Street, and corporate leadership. She also authors CFO Daily.

See full bioRight Arrow Button Icon

Latest from our Conferences

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest from our Conferences

Fortune Workplace Innovation Summit logo
ConferencesWorkplace Innovation Summit
Fortune Workplace Innovation Summit 2026 livestream
By Fortune EditorsMay 18, 2026
16 hours ago
burke
ConferencesAthletic Gear
The CEO of Trek Bicycle reads 52 books a year, hates smartphones, and thinks Milton Friedman was wrong
By Nick LichtenbergMay 6, 2026
13 days ago
mark
ConferencesHospitality
Hyatt’s CEO has built a ‘family’ culture for 20 years. Now he’s leaning on it
By Nick LichtenbergApril 30, 2026
19 days ago
sweet
ConferencesConsulting
Accenture’s Julie Sweet blew up 50 years of company history. She says the hardest part is still ahead
By Nick LichtenbergApril 29, 2026
20 days ago
anirudh
Conferencesdisruption
Cadence CEO on the AI boom and human nature: ‘there are more tools, but the human part is not different’
By Nick LichtenbergApril 23, 2026
26 days ago
‘I think it’s a mistake’: Delta CEO Ed Bastian refuses to call it ‘artificial intelligence’ because it scares people
ConferencesDelta Air Lines
‘I think it’s a mistake’: Delta CEO Ed Bastian refuses to call it ‘artificial intelligence’ because it scares people
By Nick LichtenbergApril 22, 2026
26 days ago

Most Popular

The Bezos family just donated $100 million to help achieve one of Mayor Zohran Mamdani’s top campaign promises
Politics
The Bezos family just donated $100 million to help achieve one of Mayor Zohran Mamdani’s top campaign promises
By Jake AngeloMay 12, 2026
6 days ago
While Trump insisted the Iran war would end ‘soon,’ an account in his name was buying millions in oil, defense and gold
Economy
While Trump insisted the Iran war would end ‘soon,’ an account in his name was buying millions in oil, defense and gold
By Eva RoytburgMay 18, 2026
13 hours ago
Current price of oil as of May 18, 2026
Personal Finance
Current price of oil as of May 18, 2026
By Joseph HostetlerMay 18, 2026
19 hours ago
EXCLUSIVE: An hour in the Oval Office with the CEO-in-Chief, President Trump
Politics
EXCLUSIVE: An hour in the Oval Office with the CEO-in-Chief, President Trump
By Alyson ShontellMay 18, 2026
1 day ago
Microsoft AI chief gives it 18 months—for all white-collar work to be automated by AI
AI
Microsoft AI chief gives it 18 months—for all white-collar work to be automated by AI
By Jake AngeloMay 16, 2026
3 days ago
The top foreign holders of U.S. debt may soon dump Treasury bonds and bring their money back home, potentially spiking borrowing costs
Economy
The top foreign holders of U.S. debt may soon dump Treasury bonds and bring their money back home, potentially spiking borrowing costs
By Jason MaMay 17, 2026
2 days ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.